Theranostics 2018; 8(3):644-649. doi:10.7150/thno.22161
Peptide receptor radionuclide therapy as a new tool in treatment-refractory sarcoidosis - initial experience in two patients
1. Department of Nuclear Medicine, University Hospital Würzburg, Würzburg, Germany
2. Center for Rare Diseases - Reference Center Northern Bavaria (ZESE), Würzburg, Germany
3. Department of Internal Medicine II, University Hospital Würzburg, Würzburg, Germany
4. Institute for Transfusion Medicine and Hemotherapy, University Hospital Würzburg, Würzburg, Germany
5. Department of Internal Medicine I, University Hospital Würzburg, Würzburg, Germany
Sarcoidosis is a multisystem granulomatous disorder of unknown etiology that can involve virtually all organ systems. Whereas most patients present without symptoms, progressive and disabling organ failure can occur in up to 10% of subjects. Somatostatin receptor (SSTR)-directed peptide receptor radionuclide therapy (PRRT) has recently received market authorization for treatment of SSTR-positive neuroendocrine tumors.
Methods: We describe the first case series comprising two patients with refractory multi-organ involvement of sarcoidosis who received 4 cycles of PRRT.
Results: PRRT was well-tolerated without any acute adverse effects. No relevant toxicities could be recorded during follow-up. Therapy resulted in partial response accompanied by a pronounced reduction in pain (patient #1) and stable disease regarding morphology as well as disease activity (patient #2), respectively.
Conclusion: Peptide receptor radionuclide therapy in sarcoidosis is feasible and might be a new valuable tool in patients with otherwise treatment-refractory disease. Given the long experience with and good tolerability of PRRT, further evaluation of this new treatment option for otherwise treatment-refractory sarcoidosis in larger patient cohorts is warranted.
Keywords: Sarcoidosis, somatostatin receptors, peptide receptor radionuclide therapy, PRRT
Lapa C, Kircher M, Hänscheid H, Schirbel A, Grigoleit GU, Klinker E, Böck M, Samnick S, Pelzer T, Buck AK. Peptide receptor radionuclide therapy as a new tool in treatment-refractory sarcoidosis - initial experience in two patients. Theranostics 2018; 8(3):644-649. doi:10.7150/thno.22161. Available from http://www.thno.org/v08p0644.htm